Allison Butts, PharmD, BCOP

Because ASCENT-03 allowed crossover and more than half of patients received subsequent therapy, overall survival is unlikely to show a statistically significant difference, even if a clinical benefit exists.

The ASCENT-03 trial, presented at ESMO and published in NEJM, evaluated sacituzumab govitecan (SG) versus physician’s-choice chemotherapy—including paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin—in patients with metastatic TNBC who were either PD-L1–negative or not candidates for immunotherapy.

In this segment, the experts dive into the monarchE subanalysis evaluating how Ki-67 levels before and after neoadjuvant chemotherapy inform prognosis and treatment planning for high-risk HR+, HER2– early breast cancer.

In this segment, the panel unpacks the 5-year results from the NATALEE trial, which evaluated ribociclib plus a nonsteroidal aromatase inhibitor in early HR+/HER2– breast cancer.

SABCS showcases emerging trends in breast cancer treatment, emphasizing pharmacists' vital role in medication management and patient care strategies.

If SG plus pembrolizumab becomes approved in the first-line metastatic TNBC setting, many clinicians anticipate shifting practice patterns to favor this regimen, given its promising efficacy.

From a pharmacologic standpoint, the adverse events associated with sacituzumab govitecan (SG)—particularly neutropenia and diarrhea—are consistent with the mechanism of its payload.

New findings reveal a modest overall survival benefit of abemaciclib in early breast cancer, highlighting the importance of ongoing patient education and treatment strategies.

Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.

In clinical practice, the approach to G-CSF use with sacituzumab govitecan (SG) is typically individualized based on patient-specific risk factors and prior tolerance.

This section compares the adverse-event patterns of SG plus pembrolizumab versus chemotherapy plus pembrolizumab, emphasizing differences in hematologic and non-hematologic toxicities that inform clinical monitoring.

This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.

This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.

The FDA is modernizing its approach to drug development and optimization.